| Literature DB >> 16008596 |
Diego Bogetti1, Howard N Sankary, Tomasz M Jarzembowski, Antonio Manzelli, Peter S Knight, James Thielke, Gregorio Chejfec, Scott Cotler, Jose Oberholzer, Giuliano Testa, Enrico Benedetti.
Abstract
BACKGROUND: Interventions that minimize hepatic ischemia/reperfusion injury (IRI) can expand the donor organ pool. Thymoglobulin (TG) induction therapy has been shown to ameliorate delayed graft function and possibly decrease IRI in cadaver renal transplants recipients. This controlled randomized trial was designated to assess the ability of TG to protect against IRI in liver transplant recipients. PATIENTS AND METHODS: Twenty-two cadaveric liver transplant recipients were randomized to receive either TG (1.5 mg/kg/dose) during the anhepatic period and QOD x2 doses or no TG. No differences in recipients' demographics were present and donor characteristics were similar in terms of age, cause of death, and cold ischemia time. Maintenance immunosupression consisted of Tacrolimus (or Cyclosporine) and steroids for both groups. Donor biopsies were obtained during organ procurement, cold storage and 1 h after re-vascularization. Post-operative liver function tests were monitored. Early graft function, length of stay, patient and graft survival rates, incidence of primary non-function and rate of rejection were assessed.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16008596 DOI: 10.1111/j.1399-0012.2005.00375.x
Source DB: PubMed Journal: Clin Transplant ISSN: 0902-0063 Impact factor: 2.863